| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | RNA-Based Therapies | Rare Diseases | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | RNA-Based Therapies | Rare Diseases | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | RNA-Based Therapies | Rare Diseases |
Recent Updates
Recently added Catalysts
PepGen Inc.$2.34
+0.1 (+4.34%)
D 29Pipeline Score Richly Valued Biotech · Clinical
Market Cap
104.45 M
EPS
-1.75
P/E Ratio
-
Value Trade
663.49 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
13.00 M
Operating CF
-18.43 M
Total Assets
156.29 M
Total Liabilities
22.32 M
Equity
133.98 M
D/E Ratio
12,345
-9.04 %
Week
-7.36 %
1 Month
-76.95 %
3 Month
-70.74 %
6 Month
-90.32 %
5 Year
-90.32 %
All Time
Cash Data
Cash Position
132.30 M
Monthly Burn
6.14 M
Runway
19.8 mo
Burn Trend
StableSEC Filing
May 12, 2026
Overview
Volume
2.38 M
52 Week Range
1.01 - 7.80
% held by Insiders
12.23 %
% held by Institutions
75.87 %
Enterprise Value
-11.30 M
Total Shares
69.15 M
Short %
10.06 %
Float Shares
39.76 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for PepGen Inc.
251Total events
2Upcoming
49Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 2
Event history 249
Q3 2026
◆Topline ReadoutPGN-EDODM1Clinical Data
FREEDOM2 10 mg/kg clinical results
Myotonic Dystrophy Type 1source ↗
May 21, 2026
◆Oral PresentationPGN-EDODM1Presentation
Presentations at 15th International Myotonic Dystrophy Consortium
Myotonic Dystrophy Type 1 (DM1)source ↗
May 12, 2026
▲Enrollment CompletePGN-EDODM1Trial
FREEDOM2-DM1 10 mg/kg cohort fully enrolled
Myotonic Dystrophy Type 1 (DM1)source ↗
May 12, 2026
▲Runway Guidance UpdateCorporate
Cash runway guidance: funded through FREEDOM2 12.5 mg/kg MAD readout and into 2H 2027
Q2 2026
◆Topline ReadoutPGN-EDODM1Clinical Data
FREEDOM2-DM1 10 mg/kg cohort data expected in 2H 2026
Myotonic Dystrophy Type 1 (DM1)source ↗
Mar 30, 2026
▲Topline ReadoutEDO51Clinical Data
Topline results from lowest dose (5 mg/kg) MAD cohort in Phase 2 FREEDOM2 study
Duchenne muscular dystrophysource ↗
Mar 30, 2026
◆Full ResultsPGN-EDODM1Clinical Data
PepGen reported additional clinical data from FREEDOM2 program including efficacy results
myotonic dystrophy type 1source ↗
Mar 10, 2026
◆Oral PresentationPresentation
PepGen CEO to participate in fireside chat at Leerink Global Healthcare Conference
Mar 8, 2026
◆Oral PresentationPGN-EDODM1Presentation
Oral presentation of unblinded final results from FREEDOM-DM1 at 2026 MDA Conference
Myotonic Dystrophy Type 1 (DM1)source ↗
Mar 8, 2026
◆Poster PresentationPGN-EDODM1Presentation
Poster presentation of unblinded final results from FREEDOM-DM1 at 2026 MDA Conference
Myotonic Dystrophy Type 1 (DM1)source ↗
Drug Pipeline Intelligence
D29
Pipeline Score $4M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.0x
rNPV / MCap Top 32%
Micro Cap (rank 620 of 911)
Percentile RankPepGen Inc. faces pipeline headwinds (29/100), with $50M risk-adjusted pipeline value, led by PGN-EDODM1 in Myotonic Dystrophy 1 (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PGN-EDODM1 Small molecule | Myotonic Dystrophy 1 | Phase 2 | NCT06667453 | 52% | $34M | RECRUITING | 72 | SLOW | B (63) | Mar 1, 2027 | ELEVATED_RISK | MEDIUM May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
PGN-EDODM1 Fast TrackOrphan | Myotonic Dystrophy Type 1 (DM1) | Phase 1 | 2026-03-05 | splicing correction: 5 mg/kg 12.3%, 10 mg/kg 29.1%, 15 mg/kg 53.7%; safety: PGN-EDODM1 was generally well-tolerated across all doses; treatment-emergent adverse events (TEAEs) were mild to moderate, transient, and required no intervention. Read More | PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights Read More | |
PGN-EDODM1 Fast TrackOrphan | Myotonic Dystrophy Type 1 (DM1) | Phase 1 | 2026-03-05 | splicing correction: 5 mg/kg 12.3%, 10 mg/kg 29.1%, 15 mg/kg 53.7%; safety: PGN-EDODM1 was generally well-tolerated across all doses; treatment-emergent adverse events (TEAEs) were mild to moderate, transient, and required no intervention. Read More | PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights Read More | |
PGN-EDODM1 Fast TrackOrphan | Myotonic Dystrophy Type 1 (DM1) | Phase 1 | 2026-03-05 | splicing correction: 5 mg/kg 12.3%, 10 mg/kg 29.1%, 15 mg/kg 53.7%; safety: PGN-EDODM1 was generally well-tolerated across all doses; treatment-emergent adverse events (TEAEs) were mild to moderate, transient, and required no intervention. Read More | PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PEPG
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PEPG Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PEPG▲ +6.9%on this news
PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program
PepGen has announced its participation in the 15th International Myotonic Dystrophy Consortium. The company will present clinical data related to its PGN-EDODM1 program. Further details regarding the findings or implications of the data were not provided in the announcement.
Read more →PEPG▲ +6.9%on this news
Company Presentation May 2026 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may
PepGen presented forward-looking statements regarding their investigational therapy, PGN-EDODM1, highlighting its potential in treating Myotonic Dystrophy Type 1 (DM1). The presentation stressed the advantages of the EDO platform in facilitating oligonucleotide delivery to nuclei. Positive results from clinical trials indicate an emerging safety profile, while ongoing regulatory discussions play a critical role in the therapy's future. However, potential risks include slow enrollment in clinical trials and the impact of regulatory decisions on development timelines.
Read more →PEPGPepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
PepGen has reported its financial results for the first quarter of 2026, along with recent corporate highlights. The details of the financial performance and any significant developments were not disclosed in the article. Further information may be available in subsequent releases.
Read more →PEPG▼ -58.2%on this news
PepGen Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
PepGen Inc. is facing scrutiny as Johnson Fistel, PLLP investigates potential securities law violations by the company and its executives. This investigation comes after the FDA imposed a partial clinical hold on PepGen's FREEDOM2-DM1 clinical trial, citing issues with prior studies. Following the disclosure of further clinical data, PepGen's stock experienced a sharp drop, raising concerns among investors regarding their losses. Shareholders are being encouraged to contact Johnson Fistel for assistance in recovering potential losses related to their investments in PepGen.
Read more →PEPG▼ -6.4%on this news· ran to -62% by day 3shared move
PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data
PepGen has announced topline results from the lowest dose cohort in the ongoing Phase 2 FREEDOM2 study. The results indicate favorable safety and splicing data, though specific details are not provided in the article. The study continues to progress as part of PepGen's clinical research efforts.
Read more →PEPG▼ -18.6%on this newsshared move
PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights
PepGen Inc. reported its financial results for Q4 and year-end 2025, highlighting the progress of its PGN-EDODM1 candidate for DM1. The company is well-funded, with sufficient cash to support operations into 2027. Promising data from the FREEDOM trial suggest PGN-EDODM1 could be a leading treatment option, with further results expected from ongoing trials in 2026.
Read more →PEPG▼ -18.6%on this newsshared move
PepGen Announces Regulatory Updates on FREEDOM2
PepGen Inc. has announced regulatory updates regarding its FREEDOM2 trial, which is currently on partial clinical hold by the FDA due to concerns about preclinical studies. Despite this, the company has received clearance to initiate the trial in South Korea, Australia, and New Zealand, while dosing continues in Canada and the UK. PepGen anticipates reporting data from the trial's cohorts in 2026.
Read more →PEPG▲ +5.3%on this newsshared move
March 2026 Company Presentation Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements ma
PepGen has made advancements with its investigational therapy PGN-EDODM1 for Myotonic Dystrophy Type 1. The company presents forward-looking statements highlighting its therapeutic potential and favorable safety profile of PGN-EDODM1. Regulatory clearances in various countries support ongoing patient enrollment, but the company warns of potential delays and uncertainties in clinical trials and regulatory interactions. The presentation emphasizes the innovative EDO platform’s ability to enhance oligonucleotide therapies.
Read more →PEPGPepGen to Participate in the Leerink Global Healthcare Conference
PepGen Inc. will participate in the Leerink Global Healthcare Conference on March 10, 2026. CEO James McArthur will engage in a fireside chat, discussing the company's advancements in oligonucleotide therapies aimed at treating severe neuromuscular and neurological diseases. A webcast of the event will be available for investors.
Read more →PEPGJulia Deutsch Lyra Strategic Advisory Jdeutsch@lyraadvisory.com
PepGen Inc. has appointed Joseph Vittiglio as Chief Business and Legal Officer, drawing from his two decades of experience in the biotechnology sector. Vittiglio's previous roles include positions at bluebird bio and Finch Therapeutics, where he led legal and business development efforts. His appointment comes as PepGen prepares for readouts from its PGN-EDODM1 program in 2026, indicating a strategic move to bolster its executive team during critical phases of development. The company focuses on advancing oligonucleotide therapies for severe neuromuscular and neurological diseases.
Read more →PEPG▲ +10.3%on this news
PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights – FREEDOM-DM1 15 mg/kg cohort demonstrated the highest mean splicing correction reported to date in DM1 patients – –
PepGen reported strong Q3 2025 financial results, highlighting the successful outcomes from the 15 mg/kg cohort of its FREEDOM study which showed record splicing correction in DM1 patients. The company has enrolled all patients in the 5 mg/kg cohort of the FREEDOM2 study, aimed at further validating their treatment candidate PGN-EDODM1. Additionally, a recent financing round raised $115 million, securing operations through at least mid-2027. The firm plans to share data from the ongoing trials in early 2026, maintaining a focus on improving outcomes for DM1 patients.
Read more →PEPGOctober 2025 Company Presentation Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements
PepGen's October 2025 company presentation highlights forward-looking statements regarding its investigational therapy PGN-EDODM1 for Myotonic Dystrophy Type 1. The company emphasizes the potential of its EDO platform in delivering oligonucleotides and the therapy's favorable safety profile, among other milestones. Challenges include risks associated with clinical trial progress and regulatory approvals, which could impact development timelines. The company is positioned well with designations for expedited review in the U.S. and EU.
Read more →PEPG▲ +36.4%on this news· ran to +202% by day 1
PepGen Announces Proposed Public Offering
PepGen Inc. has announced a proposed public offering of its common stock and pre-funded warrants, aimed at raising funds for its ongoing research and clinical development efforts. This offering is being managed by Leerink Partners and Stifel, who will also have a 30-day option to purchase additional shares. The actual size and conditions of the offering remain uncertain and dependent on market factors. PepGen's EDO platform continues to innovate in the treatment of neuromuscular and neurological diseases.
Read more →PEPG▲ +36.4%on this news· ran to +202% by day 1
PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients - 53.7% mean splicing correction observed following a single 15 mg/kg dose of PGN- EDODM1, with all patients showing an improvement in splicing -
PepGen announced significant positive results from its clinical trial for PGN-EDODM1, a treatment for myotonic dystrophy type 1 (DM1). In the Phase 1 FREEDOM-DM1 study, a mean splicing correction of 53.7% was observed after a single 15 mg/kg dose, surpassing previous reports. All patients showed improvements in splicing, and the treatment was generally well-tolerated. The company is set to report additional data from its FREEDOM2 trial in early 2026.
Read more →PEPG▼ -13.1%on this news
PepGen Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights – Last patient dosed in 15 mg/kg cohort of FREEDOM-DM1; on track to report topline data from study in early Q4 2025 – &#x
PepGen Inc. has reported its second-quarter financial results for 2025, highlighting progress in its lead program PGN-EDODM1 for the treatment of myotonic dystrophy type 1. The company has completed dosing in the 15 mg/kg cohort of the FREEDOM trial and is set to report topline results in early Q4 2025. Additionally, they are transitioning to the Phase 2 FREEDOM2 trial, which aims to further investigate the efficacy of multiple ascending doses of the drug. Despite a significant net loss reported this quarter, PepGen expresses confidence in its cash resources extending into mid-2026, supporting its ongoing development efforts.
Read more →PEPG▼ -13.1%on this news
PepGen Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 8, 2025 Deadline to file Lead Plaintiff Motion.
PepGen Inc. is facing a class action lawsuit following allegations of false statements related to its lead product, PGN-EDO51, during the class period from March 7, 2024, to March 3, 2025. The lawsuit claims misrepresentation regarding the safety and efficacy of PGN-EDO51, which targets Duchenne muscular dystrophy. Notably, PepGen's stock experienced significant declines in response to news of clinical holds and disappointing trial results. Investors have until August 8, 2025, to file a lead plaintiff motion.
Read more →PEPG▼ -13.1%on this news
PEPGEN (PEPG) FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds PepGen Investors of the August 8th Deadline and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against PepGen, Inc. for allegedly making false and misleading statements about the company's business and clinical trials. The lawsuit covers securities purchased between March 7, 2024 and March 3, 2025, with a deadline for investors to apply as lead plaintiff by August 8, 2025. Key allegations include concerns over the drug PGN-EDO51's effectiveness and the safety of the CONNECT2 study, which could jeopardize the company's prospects. Investors are encouraged to contact the law firm for more details on their rights.
Read more →PEPGPepGen Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; August 8, 2025 Deadline to file Lead Plaintiff Motion
PepGen Inc. is facing a class action lawsuit initiated by the Portnoy Law Firm on behalf of investors who purchased securities between March 7, 2024, and March 3, 2025. Allegations include making misleading claims about the safety and effectiveness of its lead product candidate, PGN-EDO51, and potential halts in clinical trials due to regulatory concerns from the FDA. Investors are encouraged to contact the law firm, with an August 8, 2025 deadline for filing a lead plaintiff motion. The lawsuit follows several declines in PepGen's stock price tied to disappointing clinical trial results and safety warnings.
Read more →PEPGPEPGEN (PEPG) URGENT DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds PepGen Investors of the August 8th Deadline and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has announced a class action lawsuit filed against PepGen on behalf of investors who purchased shares between March 7, 2024, and March 3, 2025. The lawsuit alleges that PepGen made materially false and misleading statements regarding the effectiveness and safety of its drug PGN-EDO51 and deficiencies in the CONNECT2 study. Investors have until August 8, 2025, to apply to be appointed lead plaintiff in the case. The allegations could significantly impact PepGen's reputation and future prospects.
Read more →PEPGPepGen Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before August 8, 2025 to Discuss Your Rights – PEPG
PepGen Inc. is facing a class action lawsuit for alleged securities law violations during the period from March 7, 2024, to March 3, 2025. The lawsuit claims that the company made false statements about its lead product candidate, PGN-EDO51, regarding its safety and effectiveness. Additionally, it is alleged that deficiencies in the CONNECT2 study could lead to a halt in its progress, potentially impacting the drug's commercial prospects. Shareholders are encouraged to register for participation in the class action.
Read more →PEPGPEPGEN INC. (NASDAQ: PEPG) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds PepGen Inc. Investors of Upcoming Deadline
Bernstein Liebhard LLP has issued a reminder to PepGen Inc. investors about an impending deadline related to a securities fraud class action lawsuit. The lawsuit alleges that the company and its senior officers misled investors regarding the safety and effectiveness of their lead product candidate, PGN-EDO51. Investors who purchased shares between March 7, 2024, and March 3, 2025, are encouraged to participate by filing papers by August 8, 2025. Representation in this class action will be on a contingency fee basis, with no fees required from shareholders.
Read more →PEPGPEPGEN (PEPG) ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Class Action Against PepGen and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has filed a class action lawsuit against PepGen, Inc. (PEPG) for alleged misleading statements about its business and products during the Class Period from March 7, 2024, to March 3, 2025. The lawsuit claims that claims surrounding the PGN-EDO51 product and the CONNECT2 study were overstated, raising concerns about their effectiveness and safety. Investors who sustained losses and acquired PepGen securities during this period are advised to contact the law firm regarding their legal options. They must apply to be lead plaintiffs by August 8, 2025.
Read more →PEPGPepGen Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before August 8, 2025 to Discuss Your Rights – PEPG
PepGen Inc. is facing a securities fraud class action lawsuit for allegedly misleading shareholders regarding its product candidate, PGN-EDO51. The lawsuit claims that the company falsely represented the efficacy and safety of PGN-EDO51, which may lead to the halting of the CONNECT2 study critical for FDA approval. Shareholders who purchased shares during the specified class period are encouraged to register with The Gross Law Firm to explore potential recovery options. Registration is required to become a lead plaintiff in the ongoing class action.
Read more →PEPGPEPGEN ALERT: Bragar Eagel & Squire, P.C. Urges Investors in PepGen, Inc. (PEPG) to Inquire About Their Rights in Class Action Lawsuit
Bragar Eagel & Squire, P.C. has initiated a class action lawsuit against PepGen, Inc. on behalf of investors who purchased shares between March 7, 2024, and March 3, 2025. The complaint alleges that the company made false statements regarding the safety and effectiveness of its product PGN-EDO51 and the adequacy of the CONNECT2 study, leading to overstated clinical and regulatory prospects. Investors are encouraged to contact the firm to discuss their rights and participation options in the legal action. The deadline for appointing a lead plaintiff is August 8, 2025.
Read more →PEPGPepGen Inc. Class Action: Levi & Korsinsky Reminds PepGen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 8, 2025 – PEPG
Levi & Korsinsky, LLP has notified investors of PepGen Inc. about a class action securities lawsuit concerning alleged fraud. The lawsuit seeks to recover losses from investors who experienced negative impacts from alleged false statements regarding the company's lead product candidate, PGN-EDO51, between March 2024 and March 2025. Key allegations include claims of the product's ineffectiveness and the dangers associated with the CONNECT2 study, which may affect its FDA approval. Investors have until August 8, 2025, to request to be appointed as lead plaintiff.
Read more →PEPGPEPGEN INC. (NASDAQ: PEPG) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds PepGen Inc. Investors of Upcoming Deadline
Bernstein Liebhard LLP has issued a notice to investors of PepGen Inc. regarding an upcoming deadline linked to a securities fraud class action lawsuit. The lawsuit pertains to claims that the company misrepresented the effectiveness and safety of its lead product candidate, PGN-EDO51. Investors who purchased shares between March 7, 2024, and March 3, 2025, are encouraged to participate in this action before the August 8, 2025, deadline. Legal representation in the class action is contingent fee-based, meaning shareholders incur no fees unless there is recovery.
Read more →PEPGPepGen Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before August 8, 2025 to Discuss Your Rights – PEPG
PepGen Inc. (NASDAQ: PEPG) faces a class-action lawsuit for alleged securities law violations related to its lead product candidate, PGN-EDO51. The complaint claims that the company issued false statements regarding the effectiveness and safety of PGN-EDO51, and that the phase two CONNECT2 study suffered from deficiencies. As a result, there are concerns about the likelihood of halting the study and overstated clinical prospects. Shareholders are encouraged to register for the class action by August 8, 2025.
Read more →PEPGPEPGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against PepGen, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has announced the filing of a class action lawsuit against PepGen, Inc. in the U.S. District Court for the Eastern District of New York. The lawsuit is on behalf of investors who purchased the company's securities from March 7, 2024, to March 3, 2025. Key allegations include misleading statements made by the company regarding the effectiveness and safety of its PGN-EDO51 drug and issues with the CONNECT2 study, suggesting that PepGen's prospects may have been overstated. Investors are encouraged to contact the law firm for participation in the lawsuit.
Read more →PEPGPEPGEN INC. (NASDAQ: PEPG) INVESTOR ALERT Investors With Large Losses in PepGen Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
A securities class action lawsuit has been initiated against PepGen Inc. for alleged misrepresentations concerning the safety and effectiveness of their lead product candidate, PGN-EDO51. This lawsuit, which encompasses securities purchased between March 7, 2024, and March 3, 2025, has prompted Bernstein Liebhard LLP to notify investors of their rights. Investors may join the class action or become lead plaintiffs by filing necessary papers by August 8, 2025. The law firm emphasizes that representation is provided on a contingency fee basis, ensuring no upfront costs for shareholders.
Read more →PEPG▲ +7.5%on this news
forward-looking statements. These risks and uncertainties include, but are not limited to risks related to: delays or failure to successfully initiate or complete our ongoing and planned development activities for our pr
PepGen Inc. announced it will discontinue development of its PGN-EDO51 program for Duchenne muscular dystrophy (DMD) after it failed to meet target dystrophin levels in the CONNECT1-EDO51 trial. The company will shift its focus to its myotonic dystrophy type 1 (DM1) program, which is in Phase 2 clinical trials. The PGN-EDO51 program did show a favorable safety profile, as all treatment-related adverse events were mild. PepGen continues to pursue its DM1 program, expecting significant results from its ongoing trials.
Read more →PEPG▲ +22.2%on this news
PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights – Reported positive DM1 patient data with mean splicing correction of 29.1% following a single dose of PGN-EDODM1 at 10 mg/kg &#x
PepGen Inc. reported its financial results for Q1 2025, revealing promising initial data for its DM1 treatment PGN-EDODM1 showing a mean splicing correction of 29.1%. The company has upcoming data expected from both the FREEDOM-DM1 and CONNECT1-EDO51 studies in the second half of 2025 and early 2026. Additionally, PepGen is focusing on extending its cash runway and has strengthened its leadership with new Board members. Despite a rising net loss compared to the previous year, the company remains optimistic about its clinical programs.
Read more →PEPG▼ -5.1%on this news· ran to -15% by day 3
About PepGen PepGen is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepG
PepGen Inc. has announced the appointment of two new directors, Lisa Wyman and Dr. Mitchell H. Finer, to its Board of Directors. Both bring extensive experience in the life sciences sector, with proven track records in clinical operations and scientific innovation. Their appointments are seen as a vital addition to the company's leadership as it advances mid-stage clinical trials and aims to leverage its Enhanced Delivery Oligonucleotide platform. PepGen focuses on developing novel therapies for severe neuromuscular and neurological diseases.
Read more →PEPG▼ -18.9%on this news
PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD Company will temporarily pause CONNECT2 and focus efforts on ongoing CONNECT1-EDO51 study of PGN-EDO51 in DMD, with 10 mg/kg results expected i
PepGen Inc. is temporarily pausing its Phase 2 CONNECT2-EDO51 study in patients with Duchenne muscular dystrophy (DMD) to focus on the ongoing CONNECT1-EDO51 study. The decision allows the company to review results from a 10 mg/kg cohort in the CONNECT1 study, with data expected in the third quarter of 2025. No new safety issues have been reported with PGN-EDO51; however, a clinical hold from the FDA and communication from Health Canada regarding safety concerns have impacted study progress.
Read more →PEPG▲ +67.2%on this news
Condensed Consolidated Balance Sheets (unaudited, in thousands) December 31
PepGen has reported positive preliminary results from the FREEDOM-DM1 trial, showing significant mean splicing correction in patients treated with PGN-EDODM1. The company is actively progressing with its clinical trials, including dosing in the CONNECT1-EDO51 trial and enrollment in the FREEDOM2 trial. Despite these encouraging results, PepGen is facing financial challenges with a significant net loss reported for the year and ongoing regulatory scrutiny from the FDA and Health Canada regarding certain trials.
Read more →PEPG▼ -6.6%on this news· ran to -37% by day 3
PepGen Announces CONNECT Program Updates BOSTON—
PepGen Inc. has announced updates on its CONNECT clinical program for PGN-EDO51 aimed at treating Duchenne muscular dystrophy. The CONNECT1 trial has fully enrolled its 10 mg/kg cohort and is expected to report data by the end of 2025. Meanwhile, a clinical hold by the FDA has delayed the initiation of CONNECT2 in the U.S., although Health Canada is permitting ongoing dosing in certain cohorts while addressing safety concerns. Overall, the initial safety data is favorable, with the company focusing on regulatory interactions.
Read more →PEPGPepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy -Company continues to advance PGN-EDO51 in CONNECT1-EDO51, with the 10 m
PepGen has announced a clinical hold imposed by the U.S. FDA on its IND application for the CONNECT2-EDO51 trial, which aims to test PGN-EDO51 in patients with Duchenne muscular dystrophy. While the company is moving forward with its CONNECT1-EDO51 study in Canada, where enrollment has been completed for the 10 mg/kg dose cohort, the hold may impact future progress for the new treatment. The FDA is expected to provide a formal letter within 30 days detailing the reasons for the hold.
Read more →PEPG▼ -21.7%on this news· ran to -37% by day 3
PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights – FREEDOM-DM1 data from 5 and 10 mg/kg cohorts in patients with DM1 expected in the first quarter of 2025 – – Study
PepGen reported its financial results for Q3 2024, showcasing progress in its clinical programs and a strengthened leadership team. The company anticipates sharing data from its FREEDOM-DM1 study cohorts in early 2025, with additional data expected throughout the year. PepGen's cash reserves are projected to sustain operations until 2026, reflecting a solid financial position as they advance their treatment programs for DM1 and DMD.
Read more →PEPGPepGen Announces Presentations at the 29 th Annual Congress of the World Muscle Society BOSTON, October 8 , 2024 -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of olig
PepGen Inc. announced it will present at the 29th Annual Congress of the World Muscle Society in Prague from October 8-12, 2024. The company will showcase preclinical and clinical data for its PGN-EDO51 therapy targeting Duchenne Muscular Dystrophy and PGN-EDODM1 for Myotonic Dystrophy Type 1. CEO James McArthur highlighted the favorable safety profile of PGN-EDO51, with no serious adverse events reported. Both therapies have received FDA designations aimed at expediting their development for serious genetic disorders.
Read more →PEPGPepGen Announces Christopher Ashton, PhD, to Retire from its Board of Directors BOSTON
PepGen Inc. announced that Christopher Ashton, PhD, will retire from its Board of Directors effective September 30, 2024. Dr. Ashton, who has served on the Board since December 2019, has been valued for his expertise and guidance. His resignation will reduce the Board's size from seven to six directors, but he leaves on good terms, citing a desire to refocus on pre-IPO companies. The company continues to pursue innovative oligonucleotide therapies aimed at treating severe neuromuscular and neurological diseases.
Read more →PEPGPepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development BOSTON
PepGen Inc. has appointed Paul Streck, M.D., MBA, as its new Executive Vice President and Head of Research & Development, effective immediately. Dr. Streck, who brings over 20 years of drug development experience, has a proven history in biopharmaceutical leadership, including notable achievements in IND approvals and product launches. His role will focus on overseeing PepGen's R&D organization as the company advances its clinical trials and therapeutic pipeline designed for severe neuromuscular and neurological diseases.
Read more →PEPG▼ -10.1%on this news
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors who purchased securities of PepGen Inc. following a significant stock price decline. On July 30, 2024, PepGen released data from its Phase 2 trial of the drug PGN-EDO51, leading to a drop of over 45% in stock value the following day. The firm aims to gather information related to the investigation in order to assist affected investors. They operate on a contingency fee basis, meaning they only recover costs if successful.
Read more →PEPGPepGen Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights – CONNECT1-EDO51 clinical trial data from low-dose cohort were reported in July. PGN-EDO51 at 5 mg/kg was well tolerated, achiev
PepGen reported its second quarter 2024 financial results, highlighting recent progress in clinical trials, particularly with PGN-EDO51 for Duchenne muscular dystrophy (DMD). The low-dose cohort reached promising outcomes, achieving mean increases in dystrophin production and was well tolerated by participants. The company has sufficient cash reserves to support operations until 2026 and plans to initiate dosing in the FREEDOM2-DM1 trial in the second half of 2024. Financial performance showed a net loss of $28.3 million, warranting attention as the company moves forward with its promising clinical pipeline.
Read more →PEPGPepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy PGN-EDO51 at 5 mg/kg was well tolerated, and all patients con
PepGen Inc. announced positive results from its ongoing CONNECT1-EDO51 Phase 2 clinical trial for PGN-EDO51, aimed at treating Duchenne muscular dystrophy. The initial cohort treated with a 5 mg/kg dose demonstrated significant increases in exon skipping and dystrophin production, indicating a favorable safety profile. All participants tolerated the treatment well and continued into the extension phase of the trial. The company looks forward to reporting results from the higher 10 mg/kg cohort and plans further studies to optimize trial design.
Read more →PEPG▼ -8.9%on this news
PepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio and Program Management and Dave Borah, CFA, as SVP, Investor Relations and Corporate Communications BOSTON
PepGen Inc. has announced the appointments of Afsaneh Mohebbi, Ph.D., as SVP of Portfolio and Program Management, and Dave Borah, CFA, as SVP of Investor Relations and Corporate Communications. These appointments are aimed at bolstering the company's executive team as they prepare for upcoming clinical milestones. Dr. Mohebbi's extensive experience in drug development and Mr. Borah's investor relations expertise are expected to contribute significantly to PepGen's efforts in advancing its oligonucleotide therapies. Both executives come with strong backgrounds in the biotech sector, promising to support the company's goals effectively.
Read more →PEPGPepGen Announces Executive Team Promotions Michelle Mellion, M.D., promoted to Chief Medical Officer Hayley Parker, Ph.D., promoted to Senior Vice President, Global Regulatory Affairs BOSTON
PepGen Inc. has announced the promotions of Michelle Mellion, M.D., to Chief Medical Officer, and Hayley Parker, Ph.D., to Senior Vice President of Global Regulatory Affairs. Both individuals have substantial experience in advancing clinical and regulatory strategies within PepGen, contributing to the company’s goal of innovating treatments for severe neuromuscular diseases. The company is poised for significant developments as it approaches data readouts and trial initiations in the near future.
Read more →PEPG▲ +5.2%on this news
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights – CONNECT1-EDO51 trial preliminary data from 5mg/kg dose cohort expected mid-2024 – – FREEDOM1-DM1 trial preliminar
PepGen Inc. reported its financial results for the first quarter of 2024, highlighting significant corporate achievements including the progress of its clinical trials for Duchenne muscular dystrophy and myotonic dystrophy. The company raised $86.3 million through common stock offerings, which is expected to support operations into 2026. Preliminary data from both the CONNECT1-EDO51 and FREEDOM1-DM1 trials is anticipated in mid to late 2024. The trials, along with new designations from the FDA, signify promising advancements in their therapeutic pipeline.
Read more →PEPGPepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
PepGen Inc. has announced that the U.S. FDA has granted orphan drug and rare pediatric disease designations for their investigational drug PGN-EDO51, aimed at treating Duchenne muscular dystrophy (DMD). This drug employs the company's Enhanced Delivery Oligonucleotide technology and targets specific mutations amenable to exon 51 skipping. PepGen is currently conducting a Phase 2 trial and is set to begin a second trial later this year. The FDA designations highlight the urgent need for innovative therapeutic options for DMD patients.
Read more →PEPGt PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy BOSTON
PepGen Inc. announced the receipt of orphan drug and rare pediatric disease designations for PGN-EDO51 from the FDA, aimed at treating Duchenne muscular dystrophy (DMD). This investigational therapeutic targets specific mutations suitable for an exon 51 skipping approach. The company is currently conducting the CONNECT1 Phase 2 trial and plans to initiate the CONNECT2 trial later this year, with preliminary data expected soon. The designations highlight the urgency for innovative treatments for DMD, a serious condition affecting many young patients.
Read more →PEPGPepGen to Participate in Upcoming Investor Conferences
PepGen Inc. has announced its participation in two upcoming investor conferences. The Stifel 2024 CNS Days will be held virtually on March 19, 2024, followed by the Needham Annual Healthcare Conference on April 8, 2024. Both events will feature management discussing PepGen's advancements in oligonucleotide therapies for neuromuscular and neurological conditions. Webcast presentations will be available on the company's Investors page.
Read more →PEPG▼ -7.3%on this news
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments - Enrollment completed for PGN-EDO51 5 mg/kg cohort in CONNECT1-EDO51 Phase 2 clinical trial in DMD patients. The Compa
PepGen reported its fourth quarter and full year 2023 financial results, highlighting significant corporate developments including the completion of enrollment for the PGN-EDO51 5 mg/kg dose cohort in the CONNECT1-EDO51 Phase 2 clinical trial for Duchenne muscular dystrophy (DMD). The company also announced the initiation of the CONNECT2-EDO51 trial in the U.K., which aims to support potential accelerated approval. Financially, PepGen secured approximately $80 million from a follow-on offering, extending its cash runway into 2026 despite experiencing growing net losses and increased research expenses.
Read more →PEPGPepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatmen
PepGen Inc. has received authorization from the UK Medicines & Healthcare Products Regulatory Agency to initiate the CONNECT2-EDO51 Phase 2 clinical trial for PGN-EDO51, targeting Duchenne muscular dystrophy through an exon 51-skipping approach. The trial will randomly assign approximately 20 participants to receive either the investigational drug or placebo over a 24-week period. Preliminary data suggest that PGN-EDO51 has favorable safety profiles and efficacy in preclinical studies. The company aims to potentially accelerate the approval process for this therapy, subject to regulatory alignment.
Read more →PEPGPepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1 BOSTON
PepGen Inc. has received Fast Track designation from the FDA for its investigational treatment PGN-EDODM1 aimed at myotonic dystrophy type 1 (DM1). This designation is intended to accelerate the development and review process for therapies targeting serious conditions with unmet needs. The company is currently evaluating PGN-EDODM1 in a Phase 1 clinical trial, with initial data anticipated in 2024. This development is significant as there are currently no approved treatments that specifically address the root cause of DM1.
Read more →PEPG▲ +17.6%on this news· ran to +42% by day 1
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock BOSTON
PepGen Inc. has announced the pricing of an underwritten offering for 7,530,000 shares of common stock at $10.635 per share, expected to raise approximately $80.1 million. The offering is set to close around February 9, 2024, pending customary closing conditions. Key players in the financing include RA Capital Management and various institutional investors. The proceeds from this offering will be used to fund ongoing research, clinical development, and general corporate purposes.
Read more →PEPGMary Beth DeLena Joins PepGen as General Counsel and Secretary BOSTON
PepGen Inc. has appointed Mary Beth DeLena as its new General Counsel and Secretary. With over 20 years of experience in advising life sciences companies, she previously served at Alnylam Pharmaceuticals, where she played a significant role in the company's success. Her legal expertise is expected to support PepGen's objectives in advancing innovative oligonucleotide therapies aimed at severe neuromuscular and neurological diseases. PepGen looks to leverage her experience to enhance compliance and strategic initiatives.
Read more →PEPGPepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping - Preliminary data from the 5 mg/kg PGN-EDO51 dose level in
PepGen Inc. announced that the first patient has been dosed in the CONNECT1-EDO51 Phase 2 clinical trial of its lead drug candidate, PGN-EDO51, for treating Duchenne muscular dystrophy (DMD). Preliminary data from the trial, expected by mid-2024, will assess safety, exon skipping, and dystrophin protein production. PGN-EDO51 uses proprietary Enhanced Delivery Oligonucleotide technology and has shown promising results in earlier Phase 1 trials, demonstrating significant levels of exon skipping in healthy volunteers.
Read more →PEPG▲ +6%on this news
PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
PepGen Inc. has announced the dosing of the first patient in their Phase 1 FREEDOM-DM1 clinical trial for PGN-EDODM1, aimed at treating myotonic dystrophy type 1 (DM1). This trial has received regulatory clearance from the UK MHRA, allowing for extended enrollment in addition to previous clearances from U.S. and Canadian agencies. The study will evaluate safety, tolerability, and clinical outcomes in approximately 24 adult patients, with results expected in 2024. The company highlighted its commitment to improving treatment options for individuals with DM1 through innovative therapies.
Read more →PEPG▲ +6%on this news
including development pathway for our product candidates, and our financial resources and cash runway. Any forward-looking statements in this press release are based on current expectations, estimates and projections onl
PepGen Inc. has announced the dosing of its first patient in the Phase 1 FREEDOM-DM1 clinical trial for PGN-EDODM1, a therapy targeting Myotonic Dystrophy Type 1 (DM1). The company received regulatory clearance from the UK Medicines and Healthcare Products Regulatory Agency (MHRA), allowing enrollment in a third country. PepGen expects to present proof-of-concept data, including safety and clinical outcome measures, in 2024. The trial aims to evaluate safety, tolerability, and therapeutic efficacy of PGN-EDODM1 in adult patients with DM1.
Read more →PEPGPepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors
PepGen Inc. announced the appointment of Dr. Howard Mayer to its Board of Directors, effective November 15, 2023. Dr. Mayer brings significant experience from his previous roles in various pharmaceutical companies, including leadership positions at Ipsen and Shire. His expertise in clinical development and rare diseases is expected to enhance PepGen's mission in developing innovative oligonucleotide therapies for severe neuromuscular and neurological disorders. Dr. Mayer expressed enthusiasm for joining the board, aligning with PepGen's commitment to advancing treatment options for patients in need.
Read more →PEPGx201c;aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends, 
PepGen Inc. has appointed Dr. Howard Mayer to its Board of Directors, effective November 15, 2023. Dr. Mayer brings a wealth of experience in clinical development and regulatory affairs from his previous roles at Ipsen Pharmaceuticals and Shire Pharmaceuticals. The company aims to advance genetic therapies for neuromuscular diseases through its Enhanced Delivery Oligonucleotide platform. This appointment is seen as a strategic move to enhance PepGen's innovative capabilities in its mission to develop impactful treatments.
Read more →PEPG▼ -10.4%on this news
PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
PepGen Inc. announced its third quarter financial results for 2023, reporting a cash position of $129.5 million, which is projected to sustain operations into 2025. The FDA recently lifted the clinical hold on the FREEDOM-DM1 study, allowing trials to proceed in the U.S. and Canada. The company also secured Orphan Drug Designation for its investigational therapeutic PGN-EDODM1 aimed at treating myotonic dystrophy type 1. Ongoing clinical trials and recent positive preclinical data from its Enhanced Delivery Oligonucleotide platform highlight PepGen's commitment to advancing neuromuscular therapies.
Read more →PEPG▲ +7.2%on this news
PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) – Lifting of FDA hold allows FREED
PepGen Inc. announced the lifting of the FDA clinical hold on its Investigational New Drug Application for the FREEDOM-DM1 Phase 1 study of PGN-EDODM1 in myotonic dystrophy type 1 (DM1). The study aims to evaluate this investigational therapy at escalating dosage levels in patients. Positive safety data has been established in preclinical trials, and results from initial patient data are expected in 2024. This clearance allows PepGen to initiate its clinical trials in both the U.S. and Canada, advancing its focus on neuromuscular diseases.
Read more →PEPGPepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology
PepGen Inc. has announced its participation in the 28th Annual Congress of the World Muscle Society from October 3-7, where details regarding its clinical studies will be presented. Presentations include findings on PGN-EDO51 for Duchenne Muscular Dystrophy and PGN-EDODM1 for Myotonic Dystrophy Type 1. The company emphasizes its commitment to developing innovative oligonucleotide therapies aimed at treating neuromuscular and neurological diseases. However, potential risks include delays in clinical trials and regulatory approvals.
Read more →PEPGPepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1 - The U.S. Food and Drug Administration (FDA) granted Orphan Drug De
PepGen Inc. has announced that it received a No Objection Letter from Health Canada to initiate the FREEDOM-DM1 Phase 1 study of PGN-EDODM1 in patients with myotonic dystrophy type 1 (DM1). In addition, PGN-EDODM1 has been granted orphan drug designation by the FDA. The trial is a randomized and placebo-controlled study designed to assess the safety and tolerability of the drug, with results expected in 2024. However, the company is also dealing with a clinical hold from the FDA regarding its IND application, which could impact timelines.
Read more →PEPGPepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company's Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences - EDO platform observed to drive 25-fold higher level
PepGen Inc. has presented promising preclinical data on its Enhanced Delivery Oligonucleotide (EDO) platform and PGN-EDODM1 program at two medical conferences. The EDO platform demonstrated a significant 25-fold improvement in oligonucleotide delivery to muscle nuclei compared to standard methods. In preclinical studies, PGN-EDODM1 showed high efficacy in reversing myotonia and correcting mis-splicing in a mouse model of Myotonic Dystrophy Type 1. The company plans to advance PGN-EDODM1 into clinical studies following successful initial results in healthy participants.
Read more →PEPGPepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment Conference
PepGen Inc. has announced its participation in several upcoming conferences, showcasing its commitment to advancing therapies for severe neuromuscular diseases. Ashling Holland, Director of Preclinical Development, will present data on PGN-EDODM1 at the Myotonic Dystrophy Foundation Annual Conference. Additionally, PepGen will have multiple poster presentations at the Ottawa Neuromuscular Disease Meeting and a corporate presentation at the H.C. Wainwright conference. These events highlight the progress of their oligonucleotide therapies and engagement with both the medical community and investors.
Read more →PEPGPepGen Reports Second Quarter 2023 Financial Results and Recent Corporate Developments – Phase 2 open-label CONNECT1-EDO51 study open in Canada – – Potentially registrational, randomized, double-blin
PepGen Inc. reported its financial results for the second quarter of 2023 along with updates on its clinical pipelines. The company has initiated the Phase 2 open-label CONNECT1-EDO51 study in Canada and plans to launch the CONNECT2-EDO51 study in the latter half of 2023. However, it faces a clinical hold from the FDA regarding the Phase 1 FREEDOM-EDODM1 study. Despite a net loss of $19.5 million for the quarter, the company maintains a strong cash position expected to last into 2025.
Read more →PEPG▲ +10.9%on this news
PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1 BOSTON
PepGen Inc. announced a delay in initiating a Phase 1 study of its candidate PGN-EDODM1 for myotonic dystrophy type 1 due to an expected clinical hold from the FDA. The company has chosen to withdraw its previous timeline guidance while addressing concerns raised by regulatory authorities. Despite this setback, PepGen is prioritizing transparency with stakeholders and remains committed to its lead program in Duchenne muscular dystrophy, which has recently received clearance from Health Canada to proceed.
Read more →PEPGPepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate a Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) BOSTON
PepGen Inc. announced a clinical hold from the FDA regarding their IND application for PGN-EDODM1, intended for a Phase 1 study on Myotonic Dystrophy Type 1. PepGen's CEO expressed disappointment but emphasized plans to work with the FDA to resolve the issue. Meanwhile, the company is pursuing development opportunities outside the U.S. and continues with its other clinical programs, such as PGN-EDO51, which has been cleared for testing in Canada.
Read more →PEPGSarah Sutton Argot Partners pepgen@argotpartners.com
PepGen Inc. announced that it has received clearance from Health Canada to initiate a Phase 2 clinical trial, CONNECT1-EDO51, for its treatment candidate PGN-EDO51 aimed at Duchenne muscular dystrophy (DMD). The trial will evaluate disease management through multiple dosing in patients amenable to exon 51 skipping. Initial results are expected to be available by mid-2024. While the data from the Phase 1 study indicated promising tolerability, potential risks include adverse reactions and trial implementation uncertainties.
Read more →PEPGPepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy
PepGen Inc. has announced the clearance from Health Canada for its Clinical Trial Application to begin the Phase 2 CONNECT1-EDO51 study of PGN-EDO51. This open label trial will evaluate the safety, tolerability, and efficacy in treating Duchenne muscular dystrophy (DMD) via an exon 51 skipping approach. Initial data from this study is projected to be available by mid-2024. The company is building on previous promising data that suggests PGN-EDO51 may effectively produce functional dystrophin protein in patients.
Read more →PEPGPepGen Reports First Quarter 2023 Financial Results and Recent Corporate Developments – Phase 2 open-label CONNECT1-EDO51 study expected to be initiated in Canada in the first half of 2023 – – Potent
PepGen Inc. has announced its financial results for Q1 2023, highlighted by a strong cash position of $165.4 million that is expected to last into 2025. The company plans to initiate several clinical trials for its oligonucleotide therapies, including the Phase 2 CONNECT1-EDO51 study in Canada and the Phase 1 FREEDOM-DM1 study in patients with myotonic dystrophy type 1 within the first half of 2023. Promising preliminary results from previous studies bolster the company's optimistic outlook for its developmental programs.
Read more →PEPGPepGen to Participate in the Bank of America Securities 2023 Healthcare Conference
PepGen Inc., a clinical-stage biotechnology company focusing on oligonucleotide therapies, announced its participation in the Bank of America Securities 2023 Healthcare Conference. The event will feature a presentation by the company's President and CEO, James McArthur, on May 11th in Las Vegas, Nevada. PepGen's technology, which includes its Enhanced Delivery Oligonucleotide platform, aims to improve treatment for severe neuromuscular and neurological diseases. A live webcast of the event will be available, along with a one-year archived replay.
Read more →PEPG▲ +23.1%on this news· ran to +35% by day 3
PepGen Announces Upcoming Data Presentations at the 2023 American Academy of Neurology Annual Meeting
PepGen Inc. has announced that it will participate in the upcoming 2023 American Academy of Neurology Annual Meeting, scheduled for April 22-27 in Boston, Massachusetts. The company will present preclinical data supporting the development of its Enhanced Delivery Oligonucleotide (EDO) platform for the treatment of myotonic dystrophy type 1 and Duchenne muscular dystrophy. Presentations will be given by Ashling Holland, Ph.D., and Michelle Mellion, M.D., during various sessions. This event marks a significant opportunity for PepGen to showcase advancements in oligonucleotide therapies.
Read more →PEPG▲ +6.1%on this news· ran to +20% by day 3shared move
PepGen to Participate in the 22nd Annual Needham Virtual Healthcare Conference
PepGen Inc. announced its participation in the 22nd Annual Needham Virtual Healthcare Conference, where CEO James McArthur will present. The presentation is scheduled for April 20th at 8:00 AM EDT and will be available via live webcast. PepGen is focused on developing next-generation oligonucleotide therapies to treat severe neuromuscular and neurological diseases, utilizing its Enhanced Delivery Oligonucleotide platform.
Read more →PEPG▼ -16.2%on this news
EMPOWERING OLIGONUCLEOTIDE THERAPEUTICS COMPANY PRESENTATION MARCH 2023 DISCLAIMERS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as ame
PepGen presented details on its Enhanced Delivery Oligonucleotide (EDO) technology aimed at overcoming oligonucleotide delivery challenges. The company plans to initiate three clinical trials in 2023, focusing on treatments for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). Their platform shows promise in improving the therapeutic activity and tolerability of oligonucleotide therapeutics, with results anticipated in 2024. However, the company acknowledges the inherent risks associated with clinical development and reliance on external partnerships.
Read more →PEPGPepGen Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Developments BOSTON
PepGen Inc. reported its financial results for Q4 and the full year 2022, highlighting significant advancements in its oligonucleotide therapy pipeline, particularly for Duchenne muscular dystrophy (DMD). The company generated first-in-human data for its lead candidate, PGN-EDO51, and plans to initiate Phase 2 studies this year. Despite these successes, PepGen recorded a net loss of $69.1 million for the year, with increased expenses linked to research and clinical trials. The company is focused on transforming treatments for severe neuromuscular diseases using its Enhanced Delivery Oligonucleotide platform.
Read more →PEPGPepGen Presents Clinical and Nonclinical Data at the 2023 Annual Muscular Dystrophy Association Clinical and Scientific Conference - In NHP, four monthly doses of 20 mg/kg of PGN-EDO51 resulted in 34.9% exon skipped tran
PepGen Inc. presented promising clinical and nonclinical data at the 2023 MDA Conference. Key highlights include substantial increases in exon skipping for PGN-EDO51 in non-human primates and plans for two upcoming Phase 2 clinical studies aimed at addressing Duchenne muscular dystrophy (DMD). Additionally, PGN-EDODM1 showed significant preclinical efficacy in addressing myotonic dystrophy type 1 (DM1). The company aims to report further results and data from these studies in 2024.
Read more →PEPGPepGen to Participate in the Stifel 2023 CNS Days Conference
PepGen Inc. announced its participation in the Stifel 2023 CNS Days Conference, where CEO James McArthur will present on March 28th. The company focuses on developing next-generation oligonucleotide therapies aimed at treating severe neuromuscular and neurological diseases. Their Enhanced Delivery Oligonucleotide platform enhances the uptake of therapeutic candidates. The presentation will be webcast live and archived for a year.
Read more →PEPG▲ +7%on this news· ran to +29% by day 1shared move
PepGen to Host Fourth Quarter and Full Year 2022 Financial Results Call
PepGen Inc. announced that it will report its fourth quarter and full year 2022 financial results on March 23, 2023. A conference call will be held for management to discuss these results and provide an update on corporate developments. The company is focused on advancing innovative oligonucleotide therapies for severe neuromuscular and neurological diseases, utilizing its Enhanced Delivery Oligonucleotide platform. However, the press release emphasizes potential risks, including challenges in clinical trials and the need for additional funding.
Read more →PEPGPepGen Announces Upcoming Data Presentations at the 2023 Annual Muscle Dystrophy Association Clinical and Scientific Conference
PepGen Inc. has announced its participation at the 2023 Muscular Dystrophy Association Annual Clinical and Scientific Conference in Dallas, Texas. The company will present data on its therapeutic candidates PGN EDO51 and PGN-EDODM1, showcasing positive results from first-in-human studies for Duchenne Muscular Dystrophy and potential impacts for Myotonic Dystrophy Type 1. Presentations are scheduled for March 22, 2023, with data to be made available on the company's investor relations website following the conference.
Read more →PEPG▼ -5.1%on this news
PepGen to Participate in the SVB Securities Global Biopharma Conference
PepGen Inc. will present at the SVB Securities Global Biopharma Conference on February 16, 2023. The company's CEO, James McArthur, will discuss PepGen's innovative Enhanced Delivery Oligonucleotide (EDO) platform, aimed at transforming treatments for severe neuromuscular and neurological disorders. The presentation can be accessed via the Investor Relations section of their website, with an available replay for 90 days after the event.
Read more →PEPGPepGen Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies - PGN-EDODM1 was well-tolerated in acute GLP studies in rodents and non-human primates (NHPs) at clinically releva
PepGen Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies - PGN-EDODM1 was well-tolerated in acute GLP studies in rodents and non-human primates (NHPs) at clinically relevant doses- - Studies conducted in patient cells indicate th
Read more →PEPG▲ +8.3%on this news· ran to +24% by day 3
PepGen Announces Positive Preclinical Data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, Three Novel Duchenne Muscular Dystrophy Candidates - In non-human primates (NHPs), high levels of exon 53 skipping were observed after a
PepGen Announces Positive Preclinical Data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, Three Novel Duchenne Muscular Dystrophy Candidates - In non-human primates (NHPs), high levels of exon 53 skipping were observed after a single dose of PGN-EDO53 almost 7-times higher than those o
Read more →PEPG▲ +12.9%on this news· ran to +30% by day 3shared move
PepGen Reports Third Quarter 2022 Financial Results and Recent Corporate Developments Boston
PepGen Reports Third Quarter 2022 Financial Results and Recent Corporate Developments Boston, November 10, 2022 PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatme
Read more →PEPGPepGen to Participate in the Stifel 2022 Healthcare Conference
BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced t
Read more →PEPGPepGen Presents Data from its Duchenne Muscular Dystrophy Program at World Muscle Society Congress
BOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, announced the pre
Read more →PEPG▲ +110.2%on this news
PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy - PGN-EDO51 exhibited the highest levels of oligonucleotide delivery and exon skipping in a clinical study fol
PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy - PGN-EDO51 exhibited the highest levels of oligonucleotide delivery and exon skipping in a clinical study following a single dose when compared to publicly available cl
Read more →PEPGPepGen Appoints Habib Dable to Board of Directors BOSTON
PepGen Appoints Habib Dable to Board of Directors BOSTON, September 22, 2022 PepGen Inc. ( PepGen ), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurolog
Read more →PEPGPepGen Appoints Habib Dable to Board of Directors
BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (“PepGen”), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the
Read more →PEPG▼ -6.7%on this news
PepGen Reports Second Quarter 2022 Financial Results and Recent Corporate Developments Boston
PepGen Reports Second Quarter 2022 Financial Results and Recent Corporate Developments Boston, August 12, 2022 PepGen Inc. ( PepGen ), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of
Read more →PEPGPepGen Appoints Caroline Godfrey, Ph.D. to the Company’s Scientific Advisory Board
BOSTON, July 22, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (“PepGen”), a Boston-based clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today an
Read more →PEPG▲ +12.7%on this news
PepGen Reports First Quarter 2022 Financial Results and Recent Corporate Developments Boston
PepGen Reports First Quarter 2022 Financial Results and Recent Corporate Developments Boston, June 16, 2022 PepGen Inc. ( PepGen ), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se
Read more →PEPGPepGen Announces Pricing of Initial Public Offering
BOSTON, May 05, 2022 (GLOBE NEWSWIRE) -- PepGen, Inc., a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the pricing of i
Read more →PEPGPepGen Announces First Participant Dosed in a Phase 1 Clinical Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
- Initiation of Phase 1 Study Marks PepGen’s Transition to a Clinical Stage Company - - This Phase 1 Healthy Normal Volunteer (HNV) Study will Evaluate Safety and Tolerability as the Primary Objective, and will Begin to Evaluate the Delivery and Target Engagement of PGN-EDO51 to
Read more →PEPGPepGen Appoints Michelle Mellion, M.D., as Senior Vice President, Head of Clinical Development
BOSTON, April 05, 2022 (GLOBE NEWSWIRE) -- PepGen, Inc., a company developing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases, today announced that it has appointed Michelle Mellion, M
Read more →PEPGPepGen Continues to Build Leadership Team with Additions of Senior Vice President, Clinical Operations and Vice President, Toxicology
BOSTON, March 30, 2022 (GLOBE NEWSWIRE) -- PepGen, Inc., advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurologic diseases, today announced that it has appointed Jennifer Cormier as Senior Vice P
Read more →PEPGPepGen Announces Approval by Health Canada of CTA to Begin First in Human Trials of PGN-EDO51 to Treat Duchenne Muscular Dystrophy
BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- PepGen Inc., a company advancing the next generation of oligonucleotide therapies for neuromuscular and neurologic diseases, today announced approval by Health Canada of PepGen’s Clinical Trial Application (CTA) authorizing initiation of
Read more →PEPGPepGen Appoints Laurie Keating as Chair of Board of Directors
BOSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced that it has appointed Laurie Keating as Chair of the company’s Board of Directors. “We are very please
Read more →PEPGPepGen Appoints Vice President of Program Management and Promotes Sonia Bracegirdle, Ph.D., to Senior Vice President, Strategy & Operations
Dr. Bracegirdle to lead expanded PepGen Strategy and Operations team Isami J. Salcedo, experienced biotechnology operations and program management professional, joins as Vice President of Program Management BOSTON, Dec. 07, 2021 (GLOBE NEWSWIRE) -- PepGen, Inc., a company advan
Read more →PEPGPepGen Bolsters R&D Team with Appointment of Jaya Goyal, Ph.D., as Executive Vice President of Research and Preclinical Development
BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced the addition of Jaya Goyal, Ph.D., as Executive Vice President of Research and Preclinical Development.
Read more →PEPGPepGen Appoints Noel Donnelly as Chief Financial Officer
BOSTON, Oct. 28, 2021 (GLOBE NEWSWIRE) -- PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced that it has appointed Noel Donnelly as Chief Financial Officer. Mr. Donnelly is an experienced finance
Read more →PEPGPepGen Welcomes Esteemed Neurologist Dr. John Day to Scientific Advisory Board
BOSTON, Oct. 13, 2021 (GLOBE NEWSWIRE) -- PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced the appointment of neuromuscular neurologist John W. Day, M.D., Ph.D., to its Scientific Advisory Board
Read more →PEPGPepGen To Present Research on Enhanced Delivery Treatments for Neuromuscular Disease at Two Scientific Conferences in September
BOSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular diseases, today announced that Chief Executive Officer James McArthur, Ph.D., will present on Pepgen’s Enhanced Delivery Oligonucleotide (EDO)
Read more →PEPGPepGen Announces New Additions to Leadership Team and Board of Directors
New appointments follow PepGen’s recent $112.5 million crossover financing to advance therapies for neuromuscular diseases PepGen is rapidly advancing lead programs in Duchenne muscular dystrophy and myotonic dystrophy type 1 to the clinic and growing its team in Boston, MA. BO
Read more →PEPGPepGen Announces Closing of $112.5 Million Crossover Financing to Advance Transformative Therapies for Neuromuscular Diseases
BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- PepGen, Inc., a company developing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced the closing of an oversubscribed $112.5 million crossover financing, led by a strong syndicate of inve
Read more →PEPGPepGen Strengthens Leadership Team with SVP of Chemistry, Manufacturing & Controls and VP of Finance Appointments
- Niels Svenstrup, Ph.D., will serve as Senior Vice President of Chemistry, Manufacturing & Controls - David Pelissier, CPA, will serve as Vice President of Finance - New leaders will support PepGen in establishing its U.S. presence, building its financial strategy and advancin
Read more →Competitive Position
How PEPG ranks across every disease it competes inCompetitive Position is a premium feature
See how PEPG ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial